We are pleased to announce that Aagami Research Team (ART) has prepared a report , highlighting select cross border Lifesicences deals (Jan 2023 – Mar 2025) in which Indian companies are involved.
The deals covered reveal robust activity across acquisitions, investments, licensing, and strategic collaborations, highlighting India’s expanding global footprint in Lifesicences.
Highlights:
· Global Expansion: Indian Lifesciences companies are active in acquisitions, licensing, and co-development deals to expand global footprints, strengthen product pipelines, and adopt advanced technologies.
· US and Europe Traditional Focus along with new emphasis on Asia: Most cross-border partnerships are with companies based in the US, Europe, and now East Asia indicating a strategic emphasis on regulated markets and high-value therapeutic segments.
· Focus on Innovation and Specialty Therapies: Key therapeutic areas include Oncology, Cardiology, CNS, Metabolic disorders, Rare diseases, vaccines, and diagnostics, reflecting a shift toward innovation-led growth and specialty medicines.
· Increased Investment Activity in Biotech and Digital Health: A growing number of investment deals signal rising interest in biotech, vaccines, and digital health platforms, aligning with global healthcare trends and unmet market needs.
If you would like to receive a complimentary copy of the report, please send your request to godwyn@aagami.com.